Home › Trials › NCT06646276

Comparing two treatments for extensive-stage small cell lung cancer

A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3 Interventional Bristol-Myers Squibb · NCT06646276

This study is testing a new treatment combination for extensive-stage small cell lung cancer to see if it works better and is safer than the standard treatment.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment530 (estimated)
Ages18 Years and up
SexAll
SponsorBristol-Myers Squibb Industry-sponsored
Drugs / interventionsNivolumab, Atezolizumab
Locations184 sites (Daphne, Alabama and 183 other locations)
Trial IDNCT06646276 on ClinicalTrials.gov

What this trial studies

This study aims to compare the efficacy and safety of a new treatment combination, BMS-986489 (which includes BMS-986012 and Nivolumab), with the standard treatment of Atezolizumab combined with Carboplatin and Etoposide for patients with extensive-stage small cell lung cancer. Participants will receive one of the two treatment regimens as their first-line therapy. The study will evaluate how well each treatment works and its safety profile in this patient population.

Who should consider this trial

Good fit: Ideal candidates for this study are individuals diagnosed with extensive-stage small cell lung cancer who are in good health and can perform normal activities with minimal assistance.

Not a fit: Patients who have previously received treatment for extensive-stage small cell lung cancer or have certain health conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for patients with extensive-stage small cell lung cancer.

How similar studies have performed: Other studies have shown promising results with similar immunotherapy approaches, indicating potential for success in this novel combination.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

* Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
* Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
* Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

Exclusion Criteria

* Participants have already received certain types of treatment for extensive stage small cell lung cancer
* Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

Daphne, Alabama and 183 other locations

+134 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Extensive-Stage Small Cell Lung CancerBMS-986489BMS-986012EtoposideCarboplatinNivolumabTIGOSfucGM1
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.